Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510199 | 0.89 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL14524708 | 0.87 | HPGD (0.42) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL14984805 | 0.84 | ALDH1A1 (0.44) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL30915198 | 0.84 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL31121260 | 0.84 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL30621106 | 0.84 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL17256399 | 0.84 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL12107853 | 0.84 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL2607961 | 0.84 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 | |
| SCHEMBL19725977 | 0.84 | HPGD (0.43) | HPGDSMN1; SMN2NPC1RAB9ADDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | HPGD 655/4885SMN1; SMN2 3302/4885NPC1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.